Investment Rating - The report maintains a "Strong Buy" rating for the company, with a target price of HKD 12 [1][7]. Core Views - The company is expected to face significant revenue declines in 2025, with projected revenues between HKD 3.55 billion and HKD 3.70 billion, representing a year-on-year decrease of 47.7% to 49.8%. The net profit attributable to shareholders is forecasted to be between HKD 520 million and HKD 580 million, down 56.1% to 60.6% [1][3]. - The second half of 2025 is anticipated to see revenues between HKD 1.05 billion and HKD 1.20 billion, a decline of 59.0% to 64.1% compared to the same period in 2024 [1][3]. - The company is focusing on channel destocking and has reduced product placements to alleviate cash flow pressures, particularly affecting its main products [7][8]. Financial Summary - Total revenue for 2024 is projected at HKD 7.067 billion, with a year-on-year growth of 0.5%. However, for 2025, revenue is expected to drop by 49.6% to HKD 3.562 billion, followed by a slight recovery in 2026 with a projected increase of 5.3% [3][8]. - Non-GAAP net profit is expected to decline significantly from HKD 1.676 billion in 2024 to HKD 525 million in 2025, reflecting a decrease of 68.7% [3][8]. - The earnings per share (EPS) is forecasted to be HKD 0.39 in 2024, dropping to HKD 0.16 in 2025, and slightly recovering to HKD 0.19 in 2027 [3][8]. Strategic Focus - The company plans to enhance its flagship product, "Da Zhen," through a new alliance model, aiming to onboard over 6,000 distributors by 2026 [7][8]. - There is a strategic emphasis on optimizing channel inventory and increasing investment in lower-tier products to penetrate the market more effectively [7][8]. - The company is actively managing its cash flow and has implemented measures to support distributors during challenging market conditions [7][8].
报表大幅纾压，大珍蓄势待发珍酒李渡（06979.HK）2025年业绩预告点评